Currently, the detection of HER2 status primarily relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques, with the criteria for interpretation mainly referencing breast cancer or gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.